Anaplastic Lymphoma Kinase
Anaplastic lymphoma kinase (ALK) was originally identified in 1994 as a tyrosine kinase activated by a chromosomal translocation in an uncommon T cell lymphoma called anaplastic large-cell lymphoma (ALCL) . Following its subsequent identification in a subset of non-small cell lung cancers (NSCLCs) in 2007 [2,3], ALK has emerged as a readily identifiable and therapeutically tractable molecular target in cancer . Activation of ALK, which occurs primarily through gene rearrangements and point mutations, is found in a spectrum of diseases including ALCL , NSCLC [2,3], inflammatory myofibroblastic tumors (IMTs) , and neuroblastoma . A variety of approaches to target ALK are in development, the most advanced of which is the ALK tyrosine kinase inhibitor crizotinib.